Publish in OALib Journal
低剂量沙利度胺联合地塞米松治疗难治性多发性骨髓瘤的临床观察
, PP. 119-120
Keywords: 沙利度胺 ,地塞米松 ,多发性骨髓瘤
Abstract:
目的为观察低剂量沙利度胺联合地塞米松治疗难治性多发性骨髓瘤(MM)的临床疗效。方法8例难治性复发性多发性骨髓瘤,沙利度胺起始剂量100mg.d-1,每3天增加50mg.d-1,1周后增至200mg.d-1,至少服用3个月。每月第1～7天联合地塞米松静脉注射10mg.d-1。结果部分缓解(PR)4例,进步2例,无效2例。6例中M蛋白平均由治疗前的45.6g.L-1下降至14g.L-1,骨髓瘤细胞由治疗前37.7%降至19.8%。差异均有统计学意义(P<0.01)。不良反应轻微,便秘最多见,均能耐受。结论低剂量沙利度胺(200mg.d-1)联合地塞米松治疗难治性多发性骨髓瘤安全有效。
References
[1 ] 叶进.沙利度胺治疗恶性血液病的机理[J].国外医学:输血及血液学分册,2002,25(2):142-144. [2 ] singlal S,mehca J,Desikan R,et al.Antihamor activity of thalidomidein refractory multiple myeloma[J].N Engl J Med,1999,341:1565-1572. [3 ] Weber D,Rankink,Gavino M,et al.Thalidomide alone or with dexame,thasone for prewiously untreated[J].Multiple Myeloma J Clin Oncol,2003,21(1):16. [4 ] Palumbo A,Ciaccone L,Bertola A,et al,low-dose thalidomide plus dexamethas one is an effective salvage therapy for advanced myeloma[J].Hematologica,2001,86(4):399. [5 ] 张之南.血液病诊断疗效标准[M].2版,北京:科学出版社,1998:373-375.
Full-Text
Please enable JavaScript to view the comments powered by Disqus.
comments powered by
Contact Us
service@oalib.com
QQ:3279437679
微信:OALib Journal
